Specifically, in a syngeneic 4T1 breast tumor model, the mitochondrial transfer inhibitor L‐778123 enhances CD8+ T cell tumor infiltration and significantly improves the efficacy of immune checkpoint inhibitors.[80] Collectively, these findings establish mitochondrial transfer as a promising and actionable therapeutic target for next‐generation immunotherapeutic strategies. This evidence concerns the gene CD8A and neoplasm.